2,238 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Fairtree Asset Management Pty Ltd

Fairtree Asset Management Pty Ltd acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,238 shares of the company’s stock, valued at approximately $365,000.

A number of other institutional investors have also recently bought and sold shares of the business. Norges Bank bought a new position in shares of Zoetis in the 4th quarter worth $824,321,000. Wellington Management Group LLP increased its holdings in Zoetis by 78.5% in the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Zoetis in the fourth quarter valued at about $196,651,000. Polen Capital Management LLC boosted its holdings in Zoetis by 17.5% during the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock worth $1,219,237,000 after buying an additional 1,116,541 shares during the last quarter. Finally, Capital Research Global Investors acquired a new position in shares of Zoetis during the 4th quarter worth about $178,688,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $166.23 on Wednesday. The company has a market capitalization of $74.01 billion, a price-to-earnings ratio of 30.39, a PEG ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The stock’s 50 day moving average is $156.53 and its 200-day moving average is $164.69.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. During the same quarter last year, the business earned $1.38 EPS. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis’s payout ratio is presently 35.91%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ZTS. Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a research report on Monday, May 12th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Stifel Nicolaus lowered their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Monday, April 14th. Finally, UBS Group lowered their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $212.75.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.18% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.